<DOC>
	<DOCNO>NCT02091661</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness two establish primary treatment patient clinically localized prostate cancer : radical retropubic prostatectomy , external-beam radiotherapy . The primary aim assess biochemical disease-free survival , overall survival , prostate cancer-specific survival . As secondary objective quality Life impact treatment ' side effect also assess .</brief_summary>
	<brief_title>Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy Clinically Localized Prostate Cancer</brief_title>
	<detailed_description>Eligible patient clinically localize ( clinical TNM classification T1 T2 ) , biopsy-proven adenocarcinoma prostate randomly treat RRP EBRT . Exclusion criterion include prior treatment prostate cancer , presence metastatic disease image study , receipt neoadjuvant androgen ablation registration , inability read understand Italian language . The institutional review board every participate centre approve study design . Every patient enrol sign informed-consent form approve institutional review board . Clinical information collect medical record include pre-treatment serum prostate-specific antigen ( PSA ) level , clinical T classification , biopsy Gleason score . Follow-up assessment complete treatment every 3 month treatment . Subjects seek primary treatment elsewhere return follow-up questionnaire beyond initial assessment exclude analysis .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age 75 year young Diagnosis prostate cancer , verify cytologic histologic examination tumor well differentiate moderately well differentiate Untreated , clinically localized prostate cancer , tumor stage T1 , T2 Prostate specific antigen ( PSA ) level â‰¤10 ng/ml Bone scan abnormality Health status would permit radical prostatectomy Life expectancy 10 year . PSA &gt; 10 ng/ml Bone scan consistent metastatic disease Other evidence cancer prostate clinically localized Life expectancy le 10 year Serum creatinine great 3 mg/dl Myocardial infarction within last 6 month Unstable angina Class III IV Severe pulmonary disease Liver failure Severe dementia Debilitating illness Malignancies , except nonmelanomatous skin cancer , last 5 year .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Clinically localized prostate cancer</keyword>
	<keyword>Radical retropubic prostatectomy</keyword>
	<keyword>External beam radiotherapy</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Quality life</keyword>
	<keyword>adverse event</keyword>
</DOC>